[go: up one dir, main page]

WO1997031651A1 - Porcine reproductive and respiratory syndrome vaccine - Google Patents

Porcine reproductive and respiratory syndrome vaccine Download PDF

Info

Publication number
WO1997031651A1
WO1997031651A1 PCT/US1997/002562 US9702562W WO9731651A1 WO 1997031651 A1 WO1997031651 A1 WO 1997031651A1 US 9702562 W US9702562 W US 9702562W WO 9731651 A1 WO9731651 A1 WO 9731651A1
Authority
WO
WIPO (PCT)
Prior art keywords
virus
vaccine
prrs
neb
swine
Prior art date
Application number
PCT/US1997/002562
Other languages
French (fr)
Inventor
Richard A. Hesse
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24442410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1997031651(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corporation filed Critical Schering Corporation
Priority to KR1019980706853A priority Critical patent/KR100297537B1/en
Priority to EE9800267A priority patent/EE04741B1/en
Priority to AU22774/97A priority patent/AU2277497A/en
Priority to BRPI9708443-3A priority patent/BR9708443B1/en
Priority to SK1194-98A priority patent/SK119498A3/en
Priority to JP09530994A priority patent/JP3135069B2/en
Priority to EP97906016A priority patent/EP0894007A1/en
Priority to CA002248182A priority patent/CA2248182C/en
Publication of WO1997031651A1 publication Critical patent/WO1997031651A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses

Definitions

  • the present invention relates to a vaccine for the treatment of porcine reproductive and respiratory syndrome (PRRS) .
  • PRRS porcine reproductive and respiratory syndrome
  • the disease is characterized by reproductive failure, respiratory disease and various clinical signs including loss of appetite, fever, dyspnea, and mild neurologic signs.
  • a major component of the syndrome is reproductive failure which manifests itself as premature births, late term abortions, pigs born weak, stillbirths, mummified fetuses, decreased farrowing rates, and delayed return of estrus.
  • Clinical signs of respiratory disease are most pronounced in pigs under 3-weeks-of-age but are reported to occur in pigs at all stages of production. Affected piglets grow slowly, have roughened hair coats, respiratory distress ("thumping"), and increased mortality.
  • the disease syndrome has been referred to by many different terms including mystery swine disease (MSD) , porcine epidemic abortion and respiratory syndrome (PEARS) , swine infertility and respiratory syndrome (SIRS) .
  • MSD mystery swine disease
  • PEARS porcine epidemic abortion and respiratory syndrome
  • SIRS swine infertility and respiratory syndrome
  • PRRS porcine reproductive and respiratory syndrome
  • An object of the present invention is to provide a novel vaccine which protects a pig against clinical disease caused by porcine reproductive and respiratory syndrome (PRRS) virus.
  • PRRS porcine reproductive and respiratory syndrome
  • a further object of the present invention is to provide a vaccine which protects a pig against the strain NEB-1 of PRRS virus.
  • the invention provides a composition of matter comprising an attenuated Porcine Respiratory and Reproductive Syndrome (PRRS) Virus which has been modified by laboratory manipulation for use in vaccination. Further the composition has phenotypic properties which allow its use for diagnostic purposes to distinguish between swine that have been naturally-infected with PRRS virus versus animals that have only been exposed to the vaccine strain.
  • PRRS virus isolate NEB-1-P94 has been deposited with American Type Culture Collection (Accession No. VR-2525) .
  • a virulent isolate of PRRS virus was obtained from tissue samples from a dead pig presented to the University of Kansas Diagnostic Laboratory. A tissue homogenate from the dead pig was inoculated onto primary swine alveolar macrophages and the presence of virus detected by cytopathic effects on inoculated but not control cultures.
  • the isolated virus (designated NEB-1) was subsequently characterized as a PRRS virus based on physical properties (ether and chloroform sensitivity, buoyant density, and lack of hemagglutinating activity) , reactivity with specific antibodies, and genetic analysis. Inoculation of the virus into nursing piglets resulted in a respiratory disease characterized by high fever, altered respiration and lung pathology consistent with viral interstitial pneumonia.
  • inoculation of the virus into pregnant sows resulted in reproductive disease characterized by mummification of fetuses, stillborn piglets, and piglets born weak that subsequently died.
  • the respiratory and reproductive disease caused by this virus was typical of the syndrome reported for PRRS virus.
  • the NEB-1 virus was attenuated by serial passage in tissue culture.
  • the virus was initially passed by inoculation of primary swine alveolar macrophage (SAM) cultures (for the first two passages) and then by serial passage on MA104 cells (available from Microbiological Associates, Inc., Rockville, MD) for a total of 94 passages.
  • SAM primary swine alveolar macrophage
  • MA104 cells available from Microbiological Associates, Inc., Rockville, MD
  • the vaccine clone designated NEB-1-P94
  • the vaccine clone was selected for impaired growth on swine alveolar macrophages, lack of reactivity with the PRRS-specific monoclonal antibody SDOW17 (ATCC HB10997), and lack of disease induction in piglets and pregnant sows.
  • the NEB-1-P94 was expanded on MA104 cells and frozen as a master seed virus, also designated PRRS-MSV-94-1, for use in vaccine development studies.
  • Vaccine is prepared using MA104 cells as the substrate
  • MA104 cells are grown to confluency in suitable tissue culture vessels, e.g. 850 cm 2 roller bottles, using Eagle's minimum essential media (EMEM) containing 5 to 10% bovine serum, 30 mM HEPES (N-2- hydroxyethylpiperazine-N'-2-ethanesulfonic acid, 2 M L- glutamine, and antibiotics (such as 30 ⁇ g/ml gentamicin) .
  • EMEM Eagle's minimum essential media
  • HEPES N-2- hydroxyethylpiperazine-N'-2-ethanesulfonic acid, 2 M L- glutamine
  • antibiotics such as 30 ⁇ g/ml gentamicin
  • tissue culture media that can support the growth of MA104 cells
  • Dulbecco' s modified essential media [DMEM] DMEM
  • Medium 199 or others
  • Confluent monolayers of MA104 cells are inoculated with NEB-1-P94 virus at a multiplicity of infection (MOI) in the range of 1:5 to 1:1000, and, preferably in the range of 1:10. Following incubation for three to five days at 37°C, culture supernatant fluids are harvested by decanting.
  • MOI multiplicity of infection
  • Virus fluids are titered by making serial dilutions in EMEM supplemented as above and inoculation of 0.2 ml per well into at least four replicate wells of confluent MA104 or MARC 145 cells in a 96-well tissue culture plate. Cultures are incubated for five days at 37°C, 3-5% CO 2 in a humidified chamber and observed for cytopathic effects. Titers (50% endpoints) are calculated according to the methods of Spearman and Karber (Methods in Virology, Volume IV, K. Maramorosch and H. Koprowski (Eds) . Academic Press, New York, 1977) .
  • Cells may be fixed with 80% acetone and tested for lack of reactivity with SDOW17 and positive reactivity with V017 or EP147 (available from Dr. E. Nelson, South Dakota State University, Brookings, SD) (expected positive result) monoclonal antibodies to confirm phenotypic identity of the virus.
  • virus fluids are incubated with a chemical inactivation agent.
  • inactivation agents include formaldehyde, glutaraldehyde, binary ethyleneimine, or beta-propiolactone.
  • Virus fluids are then stored at 4°C until formulated into vaccine.
  • Vaccine is prepared by mixing virus fluids (containing 10 6 to 10 9 TCID 50 of virus; based on preinactivation titers) with a physiologically acceptable diluent (such as EMEM, Hank's Balanced Salt Solution, Phosphate Buffered Saline) and an immune-stimulating adjuvant (such as mineral oil, vegetable oil, aluminum hydroxide, saponin, non-ionic detergents, squalene, block co-polymers or other compounds known in the art, used alone or in combination) .
  • a vaccine dose is typically between 1 and 5 ml.
  • virus fluids are stored frozen at -50°C or colder until use.
  • Virus fluids within the range of 10 4 - 0 and 10 7 - 0 TCIDso/dose and preferably containing 10 6 - 0 TCID 5 o/dose are diluted with a physiologically suitable diluent (such as EMEM, Hank's Balanced Salt Solution, Phosphate Buffered Saline) and a physiologically suitable mixture of compounds designed to stabilize the virus.
  • a physiologically suitable diluent such as EMEM, Hank's Balanced Salt Solution, Phosphate Buffered Saline
  • Compounds known in the art that can be used alone or in combination to stabilize viruses include sucrose, lactose, N-Z amine, glutathione, neopeptone, gelatin, dextran and tryptone.
  • Vaccine is stored frozen (-50°C or colder) or lyophilized with storage at 4°C until use.
  • the vaccine typically has a dose size range of 1 to 5 ml, and preferably 2 m
  • the vaccine is administered to the pig orally, intranasally or parenterally.
  • parenteral routes of administration include intradermal, intramuscular, intravenous, intraperitoneal and subcutaneous routes of administration.
  • the present vaccine When administered as a solution, the present vaccine may be prepared in the form of an aqueous solution, a syrup, an elixir, or a tincture.
  • Such formulations are known in the art, and are prepared by dissolution of the antigen and other appropriate additives in the appropriate solvent systems.
  • solvents include water, saline, ethanol, ethylene glycol, glycerol, Al fluid, etc.
  • Suitable additives known in the art include certified dyes, flavors, sweeteners, and antimicrobial preservatives, such as thimerosal (sodium ethylmercuri- thiosalicylate) .
  • Such solutions may be stabilized, for example, by addition of partially hydrolyzed gelatin, sorbitol, or cell culture medium, and may be buffered by methods known in the art, using reagents known in the art, such as sodium hydrogen phosphate, sodium dihydrogen phosphate, potassium hydrogen phosphate and/or potassium dihydrogen phosphate.
  • Liquid formulations may also include suspensions and emulsions.
  • Parenteral dosage forms designed for injection into body fluid systems, require proper isotonicity and pH buffering to the corresponding levels of porcine body fluids. Parenteral formulations must also be sterilized prior to use.
  • Isotonicity can be adjusted with sodium chloride and other salts as needed.
  • Other solvents such as ethanol or propylene glycol, can be used to increase solubility of ingredients of the composition and stability of the solution.
  • Further additives which can be used in the present formulation include dextrose, conventional antioxidants and conventional chelating agents, such as ethylenediamine tetraacetic acid (EDTA) .
  • EDTA ethylenediamine tetraacetic acid
  • a booster vaccination may be administered two to four weeks after the initial immunization.
  • the vaccination regimen is typically performed up to 6 weeks prior to and 1 week after breeding.
  • vaccination may be given as early as 3 weeks of age.
  • the response to vaccination can be monitored by measuring antibody titer directed against PRRS virus using enzyme-linked immunosorbent assay (ELISA) , serum neutralization assay, indirect immunofluorescence, or Western blot.
  • ELISA enzyme-linked immunosorbent assay
  • the vaccine strain has phenotypic properties that can be used for diagnosis in swine of wild type PRRS infection versus exposure to only the vaccine strain.
  • Animals exposed to field strains of PRRS virus may be distinguished from animals exposed only to the NEB-1-P94 vaccine strain by measurement of the antibody response to the epitope recognized by monoclonal antibody (MAb) SD0W17. The presence of antibodies reactive with the SD0W17 epitope is indicative of wild type virus exposure,
  • Measurement of antibodies to the SD0W17 epitope can be accomplished using a competitive ELISA. Plates (96-well) are coated with the NEB-1 PRRS virus (or other PRRS viruses expressing the SDOW17 epitope) . Plates are then incubated with pig serum from test animals and enzyme-labelled (for example conjugated to horseradish peroxidase) SD0W17 monoclonal antibody. The ability of pig sera to recognize the SD0W17 epitope is measured by the inhibition of enzyme-linked SD0W17 MAb binding to the plate as detected by lack of enzyme substrate color conversion. Alternatively, a direct ELISA may be used.
  • the amino acid sequence comprising the SD0W17 epitope can be prepared as a synthetic peptide or by recombinant DNA expression methods in a suitable vector system such as E. coli . Plates coated with the SD0W17 antigen are incubated with pig serum. Binding of swine antibodies to the SD0W17 antigen is detected by incubation with enzyme-conjugated anti-swine immunoglobulin antisera followed by incubation with enzyme substrate and detection of a color change.
  • the NEB-1-P94 vaccine strain virus at five passages from the master seed was characterized for growth on MA104, MARC 145, and swine alveolar macrophages.
  • Swine alveolar macrophages (SAM) were obtained by bronchi-alveolar lavage with saline followed by centrifugation to pellet the cells. Macrophages were resuspended in EMEM with 10% fetal bovine serum and 50 ⁇ g/ml gentamicin and plated at approximately 7 x 10 4 cells per well of 96-well tissue culture plates.
  • MA104 cells and MARC 145 cells were plated in 96-well tissue culture plates in media (EMEM containing 10% fetal bovine serum, 30 mM HEPES, 2 mM L-glutamine, and 50 ⁇ g/ml gentamicin) .
  • NEB-1-P94 or the parental NEB-1 virus were serially diluted in media and 0.2 ml of each dilution inoculated into replicate wells of 96-well plates containing SAM, MA104, or MARC 145 cells. Cultures were incubated for 5 days at 37°C, 3% to 5% CO 2 , in a humidified chamber and monitored for cytopathic effects typical of PRRS virus. Titers (50% endpoints) were calculated according to the method of Spearman and Karber.
  • the NEB-1-P94 showed reduced titers or unmeasurable titers on three separate SAM cultures compared to the titers obtained on MA104 and MARC
  • gnotobiotic piglets (seven to 10 days of age) from PRRS seronegative sows were inoculated intranasally (3 ml/nare) with NEB-1-P94 master seed virus (10 5 - 3 TCIDso/ml) . Piglets were observed for clinical signs of respiratory disease and the vaccine strain virus was re-isolated from serum at five days post-inoculation. Serum from the first group of pigs was used to intranasally inoculate a second group of gnotobiotic pigs which were monitored in the same way. This process was repeated for a total of five serial backpassages in piglets in order to determine whether the vaccine strain could revert to a virulent state.
  • Vaccine virus was recovered from each successive animal passage, however, respiratory disease was not observed in the gnotobiotic pigs.
  • virus isolated from the fifth backpassage pigs was intranasally inoculated into one-week-old and three-week-old conventional piglets (approximately 10 5 - 3 TCID 5 o/ml was administered per piglet) .
  • Animals were monitored for 42 days after virus inoculation and no clinical disease signs (i.e. prolonged high fever, respiratory signs, lung lesions) consistent with virulent PRRS infection were found. Therefore, the NEB-1-P94 virus was concluded to be avirulent for induction of respiratory disease in piglets.
  • NEB-1-P94 virus was examined for its ability to cause reproductive disease.
  • PRRS seronegative sows at 85 days of gestation were inoculated intranasally (3 ml/nare) with the master seed vaccine strain (10 4 - 5 TCIDso/ml) • All sows farrowed at their expected time and 96% of the piglets were born live and healthy. By comparison, uninoculated control sows gave birth to litters where 87% of the piglets were live and healthy.
  • MA104 cells infected with parental strain NEB-1 or the vaccine strain NEB-1-P94 virus were examined for reactivity with monoclonal antibodies specific for the PRRS virus by indirect immunofluorescence. Briefly, 96-well plates of confluent MA104 cells were fixed with 80% acetone for 10 minutes at 2 days after infection with each virus. Monolayers were then incubated with SD0W17, V017, or EP147 monoclonal antibodies. Following washing, monoclonal antibody reactivity with each virus was detected by incubation with fluorescein isothiocyanate conjugated anti-mouse IgG followed by washing and examination for fluorescence by microscopy. Positive fluorescence was noted with all three monoclonal antibodies for the NEB-1 parental strain (Table 2) .
  • the vaccine strain had lost reactivity with the SD0W17 monoclonal antibody but tested positive with the other two monoclonal antibodies.
  • These data indicate that the NEB-1- P94 strain had lost expression of epitope recognized by the SD0W17 antibody.
  • the loss of reactivity with this monoclonal antibody most likely represents genetic mutation in the RNA sequence of NEB-1-P94 which resulted in an altered amino acid sequence in the nucleocapsid protein region recognized by SD0W17.
  • Vaccine was prepared by inoculation of confluent roller bottles of MA104 cells with NEB-1-P94 (4 passages from the master seed) at a multiplicity of infection of approximately 1:10 in EMEM containing 10% fetal bovine serum, 2 mM L-glutamine, and 30 ⁇ g/ml gentamicin. Cultures were incubated for three days at 37°C and then supernatant fluids were harvested by decanting.
  • Virus fluids were diluted 50% (v/v) with stabilizer (75 g/L tryptone, 30 g/L dextran, 2 g/L gelatin, 100 g/L lactose, 2 g/L sodium gluta ate, 1.05 g/L KH 2 PO 4 , 2.5 g/L K 2 HP0 4 , lOg/L albumin fraction V) , frozen, and lyophilized.
  • stabilizer 75 g/L tryptone, 30 g/L dextran, 2 g/L gelatin, 100 g/L lactose, 2 g/L sodium gluta ate, 1.05 g/L KH 2 PO 4 , 2.5 g/L K 2 HP0 4 , lOg/L albumin fraction V
  • Vaccine was rehydrated with sterile deionized water and 2 ml (10 5 - 1 TCIDsrj/ml) administered intramuscularly to gilts four to six weeks prior to breeding.
  • vaccinated and unvaccinated control gilts were challenged by intranasal administration of NEB-1 virus (approximately 10 6 - 3 TCID 50 ) • Animals were monitored through seven weeks after farrowing for signs of fetal or neonatal death attributed to PRRS virus.
  • PRRS viremia developed in 11/12 (92%) of control sows and 100% of their live-born piglets. PRRS infection during pregnancy resulted in 16% death loss at parturition (large mummies and stillborn pigs) in the control group (Table 3) compared to only 6% death loss in vaccinated sows.
  • Vaccine was prepared by inoculation of confluent roller bottles of MA104 cells with NEB-1-P94 (at 4 passages from the master seed) at a multiplicity of infection of approximately 1:10 in EMEM containing 10% fetal bovine serum, 2 mM L-glutamine, and 30 ⁇ g/ml gentamicin. Cultures were incubated for five days at 37°C and then supernatant fluids were harvested by decanting.
  • Virus fluids were diluted 50% (v/v) with stabilizer (75 g/L tryptone, 30 g/L dextran, 2 g/L gelatin, 100 g/L lactose, 2 g/L sodium glutamate, 1.05 g/L KH 2 PO 4 , 2.5 g/L K 2 HP0 4 , 10 g/L albumin fraction V) , frozen, and lyophilized.
  • stabilizer 75 g/L tryptone, 30 g/L dextran, 2 g/L gelatin, 100 g/L lactose, 2 g/L sodium glutamate, 1.05 g/L KH 2 PO 4 , 2.5 g/L K 2 HP0 4 , 10 g/L albumin fraction V
  • Vaccine was rehydrated with sterile deionized water and 1 ml (10 4 - 9 TCID 50 /ml) administered intramuscularly to PRRS seronegative piglets at three weeks of age.
  • piglets were challenged with virulent NEB-1 PRRS virus by intranasal route as described for gilts (Example 4) . Piglets were monitored for respiratory disease signs for 14 days after challenge. All unvaccinated control piglets developed clinical signs of respiratory disease compared with 3/40 (8%) of vaccinated animals. Vaccination resulted in a statistically significant reduction in fever, respiratory signs, and clinical illness in vaccinated animals compared to controls (Table 4) . This study clearly demonstrated the efficacy of the vaccine in the prevention of respiratory disease caused by PRRS virus in young pigs. Table 4. Summary of Clinical Disease in Vaccinated and Control Animals Following PRRS Virus Challenge
  • Vaccinates 0 14 20 20 14 10 10 20 2 14 10 10 4 4 NA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

The invention discloses a vaccine and methods for the treatment of porcine reproductive and respiratory syndrome. The vaccine is derived from the viral agent NEB-1-P94, deposited at the American Type Culture Collection under accession number VR-2525. Further, the invention discloses a vaccine virus with phenotypic characteristics which can be distinguished from wild type PRRS virus.

Description

PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE
BACKGROUND OF THE INVENTION
The present invention relates to a vaccine for the treatment of porcine reproductive and respiratory syndrome (PRRS) .
In 1987, the swine-producing industry in the United States experienced an unknown infectious disease which had a serious economic impact on the swine industry. The disease syndrome was reported in Europe including Germany, Belgium, the Netherlands, Spain and England.
The disease is characterized by reproductive failure, respiratory disease and various clinical signs including loss of appetite, fever, dyspnea, and mild neurologic signs. A major component of the syndrome is reproductive failure which manifests itself as premature births, late term abortions, pigs born weak, stillbirths, mummified fetuses, decreased farrowing rates, and delayed return of estrus. Clinical signs of respiratory disease are most pronounced in pigs under 3-weeks-of-age but are reported to occur in pigs at all stages of production. Affected piglets grow slowly, have roughened hair coats, respiratory distress ("thumping"), and increased mortality.
The disease syndrome has been referred to by many different terms including mystery swine disease (MSD) , porcine epidemic abortion and respiratory syndrome (PEARS) , swine infertility and respiratory syndrome (SIRS) . The name now commonly used is porcine reproductive and respiratory syndrome (PRRS) ; this term will be employed throughout this patent application.
It is an object of the invention to provide a vaccine which protects a pig against clinical disease caused by PRRS. Another object is to provide a vaccine which, when administered to a breeding swine herd, will reduce the presence of PRRS in their population.
SUMMARY OF THE INVENTION
An object of the present invention is to provide a novel vaccine which protects a pig against clinical disease caused by porcine reproductive and respiratory syndrome (PRRS) virus.
A further object of the present invention is to provide a vaccine which protects a pig against the strain NEB-1 of PRRS virus.
It is a further object of the present invention to provide a method of protecting a pig against clinical disease caused by a porcine reproductive and respiratory disease virus.
It is a further object of this invention to provide a vaccine virus with phenotypic characteristics which can be distinguished from wild type PRRS virus.
DETAILED DESCRIPTION OF THE INVENTION
The invention provides a composition of matter comprising an attenuated Porcine Respiratory and Reproductive Syndrome (PRRS) Virus which has been modified by laboratory manipulation for use in vaccination. Further the composition has phenotypic properties which allow its use for diagnostic purposes to distinguish between swine that have been naturally-infected with PRRS virus versus animals that have only been exposed to the vaccine strain. The PRRS virus isolate NEB-1-P94 has been deposited with American Type Culture Collection (Accession No. VR-2525) .
A virulent isolate of PRRS virus was obtained from tissue samples from a dead pig presented to the University of Nebraska Diagnostic Laboratory. A tissue homogenate from the dead pig was inoculated onto primary swine alveolar macrophages and the presence of virus detected by cytopathic effects on inoculated but not control cultures. The isolated virus (designated NEB-1) was subsequently characterized as a PRRS virus based on physical properties (ether and chloroform sensitivity, buoyant density, and lack of hemagglutinating activity) , reactivity with specific antibodies, and genetic analysis. Inoculation of the virus into nursing piglets resulted in a respiratory disease characterized by high fever, altered respiration and lung pathology consistent with viral interstitial pneumonia. Additionally, inoculation of the virus into pregnant sows resulted in reproductive disease characterized by mummification of fetuses, stillborn piglets, and piglets born weak that subsequently died. The respiratory and reproductive disease caused by this virus was typical of the syndrome reported for PRRS virus.
The NEB-1 virus was attenuated by serial passage in tissue culture. The virus was initially passed by inoculation of primary swine alveolar macrophage (SAM) cultures (for the first two passages) and then by serial passage on MA104 cells (available from Microbiological Associates, Inc., Rockville, MD) for a total of 94 passages. During this process, virus clones were isolated by plaque purification and characterized for phenotypic properties. The vaccine clone, designated NEB-1-P94, was selected for impaired growth on swine alveolar macrophages, lack of reactivity with the PRRS-specific monoclonal antibody SDOW17 (ATCC HB10997), and lack of disease induction in piglets and pregnant sows. The NEB-1-P94 was expanded on MA104 cells and frozen as a master seed virus, also designated PRRS-MSV-94-1, for use in vaccine development studies.
Vaccine is prepared using MA104 cells as the substrate
(however alternate cell lines that support the growth of PRRS virus such as MARC 145 [available from Dr. Wang, Agriculture Research Station, Clay Center NE] cells can also be used) . MA104 cells are grown to confluency in suitable tissue culture vessels, e.g. 850 cm2 roller bottles, using Eagle's minimum essential media (EMEM) containing 5 to 10% bovine serum, 30 mM HEPES (N-2- hydroxyethylpiperazine-N'-2-ethanesulfonic acid, 2 M L- glutamine, and antibiotics (such as 30 μg/ml gentamicin) . Alternate tissue culture media that can support the growth of MA104 cells such as Dulbecco' s modified essential media [DMEM] , Medium 199, or others can also be used. Confluent monolayers of MA104 cells are inoculated with NEB-1-P94 virus at a multiplicity of infection (MOI) in the range of 1:5 to 1:1000, and, preferably in the range of 1:10. Following incubation for three to five days at 37°C, culture supernatant fluids are harvested by decanting.
Virus fluids are titered by making serial dilutions in EMEM supplemented as above and inoculation of 0.2 ml per well into at least four replicate wells of confluent MA104 or MARC 145 cells in a 96-well tissue culture plate. Cultures are incubated for five days at 37°C, 3-5% CO2 in a humidified chamber and observed for cytopathic effects. Titers (50% endpoints) are calculated according to the methods of Spearman and Karber (Methods in Virology, Volume IV, K. Maramorosch and H. Koprowski (Eds) . Academic Press, New York, 1977) . Cells may be fixed with 80% acetone and tested for lack of reactivity with SDOW17 and positive reactivity with V017 or EP147 (available from Dr. E. Nelson, South Dakota State University, Brookings, SD) (expected positive result) monoclonal antibodies to confirm phenotypic identity of the virus.
For the preparation of a killed vaccine, virus fluids are incubated with a chemical inactivation agent. Examples of inactivation agents include formaldehyde, glutaraldehyde, binary ethyleneimine, or beta-propiolactone. Virus fluids are then stored at 4°C until formulated into vaccine. Vaccine is prepared by mixing virus fluids (containing 106 to 109 TCID50 of virus; based on preinactivation titers) with a physiologically acceptable diluent (such as EMEM, Hank's Balanced Salt Solution, Phosphate Buffered Saline) and an immune-stimulating adjuvant (such as mineral oil, vegetable oil, aluminum hydroxide, saponin, non-ionic detergents, squalene, block co-polymers or other compounds known in the art, used alone or in combination) . A vaccine dose is typically between 1 and 5 ml. For a live vaccine formulation, virus fluids are stored frozen at -50°C or colder until use. Virus fluids within the range of 104-0 and 107-0 TCIDso/dose and preferably containing 106-0 TCID5o/dose are diluted with a physiologically suitable diluent (such as EMEM, Hank's Balanced Salt Solution, Phosphate Buffered Saline) and a physiologically suitable mixture of compounds designed to stabilize the virus. Compounds known in the art that can be used alone or in combination to stabilize viruses include sucrose, lactose, N-Z amine, glutathione, neopeptone, gelatin, dextran and tryptone. Vaccine is stored frozen (-50°C or colder) or lyophilized with storage at 4°C until use. The vaccine typically has a dose size range of 1 to 5 ml, and preferably 2 ml.
For prophylaxis against PRRS-induced disease, the vaccine is administered to the pig orally, intranasally or parenterally. Examples of parenteral routes of administration include intradermal, intramuscular, intravenous, intraperitoneal and subcutaneous routes of administration.
When administered as a solution, the present vaccine may be prepared in the form of an aqueous solution, a syrup, an elixir, or a tincture. Such formulations are known in the art, and are prepared by dissolution of the antigen and other appropriate additives in the appropriate solvent systems. Such solvents include water, saline, ethanol, ethylene glycol, glycerol, Al fluid, etc. Suitable additives known in the art include certified dyes, flavors, sweeteners, and antimicrobial preservatives, such as thimerosal (sodium ethylmercuri- thiosalicylate) . Such solutions may be stabilized, for example, by addition of partially hydrolyzed gelatin, sorbitol, or cell culture medium, and may be buffered by methods known in the art, using reagents known in the art, such as sodium hydrogen phosphate, sodium dihydrogen phosphate, potassium hydrogen phosphate and/or potassium dihydrogen phosphate.
Liquid formulations may also include suspensions and emulsions. The preparation of suspensions, for example using a colloid mill, and emulsions, for example using a homogenizer, is known in the art.
Parenteral dosage forms, designed for injection into body fluid systems, require proper isotonicity and pH buffering to the corresponding levels of porcine body fluids. Parenteral formulations must also be sterilized prior to use.
Isotonicity can be adjusted with sodium chloride and other salts as needed. Other solvents, such as ethanol or propylene glycol, can be used to increase solubility of ingredients of the composition and stability of the solution. Further additives which can be used in the present formulation include dextrose, conventional antioxidants and conventional chelating agents, such as ethylenediamine tetraacetic acid (EDTA) .
A booster vaccination may be administered two to four weeks after the initial immunization. For the prevention of reproductive disease, the vaccination regimen is typically performed up to 6 weeks prior to and 1 week after breeding. For the prevention of respiratory disease in piglets, vaccination may be given as early as 3 weeks of age. The response to vaccination can be monitored by measuring antibody titer directed against PRRS virus using enzyme-linked immunosorbent assay (ELISA) , serum neutralization assay, indirect immunofluorescence, or Western blot.
The vaccine strain has phenotypic properties that can be used for diagnosis in swine of wild type PRRS infection versus exposure to only the vaccine strain. Animals exposed to field strains of PRRS virus may be distinguished from animals exposed only to the NEB-1-P94 vaccine strain by measurement of the antibody response to the epitope recognized by monoclonal antibody (MAb) SD0W17. The presence of antibodies reactive with the SD0W17 epitope is indicative of wild type virus exposure,
Measurement of antibodies to the SD0W17 epitope can be accomplished using a competitive ELISA. Plates (96-well) are coated with the NEB-1 PRRS virus (or other PRRS viruses expressing the SDOW17 epitope) . Plates are then incubated with pig serum from test animals and enzyme-labelled (for example conjugated to horseradish peroxidase) SD0W17 monoclonal antibody. The ability of pig sera to recognize the SD0W17 epitope is measured by the inhibition of enzyme-linked SD0W17 MAb binding to the plate as detected by lack of enzyme substrate color conversion. Alternatively, a direct ELISA may be used. The amino acid sequence comprising the SD0W17 epitope can be prepared as a synthetic peptide or by recombinant DNA expression methods in a suitable vector system such as E. coli . Plates coated with the SD0W17 antigen are incubated with pig serum. Binding of swine antibodies to the SD0W17 antigen is detected by incubation with enzyme-conjugated anti-swine immunoglobulin antisera followed by incubation with enzyme substrate and detection of a color change.
The following examples describe in detail the invention. It will be apparent to those skilled in the art that modification of materials and methods may be practiced without departing from the purpose and intent of this disclosure.
EXAMPLE 1
Phenotypic Characterization of NEB-1-P94 for Growth on Alveolar Macrophages
The NEB-1-P94 vaccine strain virus at five passages from the master seed was characterized for growth on MA104, MARC 145, and swine alveolar macrophages. Swine alveolar macrophages (SAM) were obtained by bronchi-alveolar lavage with saline followed by centrifugation to pellet the cells. Macrophages were resuspended in EMEM with 10% fetal bovine serum and 50 μg/ml gentamicin and plated at approximately 7 x 104 cells per well of 96-well tissue culture plates. MA104 cells and MARC 145 cells were plated in 96-well tissue culture plates in media (EMEM containing 10% fetal bovine serum, 30 mM HEPES, 2 mM L-glutamine, and 50 μg/ml gentamicin) . NEB-1-P94 or the parental NEB-1 virus were serially diluted in media and 0.2 ml of each dilution inoculated into replicate wells of 96-well plates containing SAM, MA104, or MARC 145 cells. Cultures were incubated for 5 days at 37°C, 3% to 5% CO2, in a humidified chamber and monitored for cytopathic effects typical of PRRS virus. Titers (50% endpoints) were calculated according to the method of Spearman and Karber. The NEB-1-P94 showed reduced titers or unmeasurable titers on three separate SAM cultures compared to the titers obtained on MA104 and MARC
145 cells (Table 1) . This is a phenotypic change compared to the parental strain which showed similar titers on all of the cultures tested. Therefore, impaired growth on swine alveolar macrophages was a selected phenotypic marker for the vaccine strain NEB-1-P94.
Table 1. Comparison of Growth of the NEB-1-P94 Virus on Various Cell Types
Virus Titer* on Titer* on Titer* on Titer* on Titer* on MA104 MARC 145 SAM 7 SAM 8 SAM 22
NEB-1-P94 5.3 6.1 <1.2 2.5 <1.2
NEB-1 5.2 6.5 5.2 6.5 6.5
^Titer = logio TCIDso/ml (limit of detection in this assay = 1.2! EXAMPLE 2
Phenotypic Characterization of NEB-1-P94 for Lack of Virulence in Swine
Four gnotobiotic piglets (seven to 10 days of age) from PRRS seronegative sows were inoculated intranasally (3 ml/nare) with NEB-1-P94 master seed virus (105-3 TCIDso/ml) . Piglets were observed for clinical signs of respiratory disease and the vaccine strain virus was re-isolated from serum at five days post-inoculation. Serum from the first group of pigs was used to intranasally inoculate a second group of gnotobiotic pigs which were monitored in the same way. This process was repeated for a total of five serial backpassages in piglets in order to determine whether the vaccine strain could revert to a virulent state. Vaccine virus was recovered from each successive animal passage, however, respiratory disease was not observed in the gnotobiotic pigs. In addition, virus isolated from the fifth backpassage pigs was intranasally inoculated into one-week-old and three-week-old conventional piglets (approximately 105-3 TCID5o/ml was administered per piglet) . Animals were monitored for 42 days after virus inoculation and no clinical disease signs (i.e. prolonged high fever, respiratory signs, lung lesions) consistent with virulent PRRS infection were found. Therefore, the NEB-1-P94 virus was concluded to be avirulent for induction of respiratory disease in piglets.
Next the NEB-1-P94 virus was examined for its ability to cause reproductive disease. PRRS seronegative sows at 85 days of gestation were inoculated intranasally (3 ml/nare) with the master seed vaccine strain (104-5 TCIDso/ml) • All sows farrowed at their expected time and 96% of the piglets were born live and healthy. By comparison, uninoculated control sows gave birth to litters where 87% of the piglets were live and healthy.
Therefore, the vaccine strain NEB-1-P94 failed to induced reproduction disease typical of a virulent PRRS virus (See Example 4) . These data confirmed the avirulent phenotype of the vaccine strain, NEB-1-P94. EXAMPLE 3
Phenotypic Characterization of NEB-1-P94 for Reactivity with PRRS Virus-Specific Monoclonal Antibodies
MA104 cells infected with parental strain NEB-1 or the vaccine strain NEB-1-P94 virus were examined for reactivity with monoclonal antibodies specific for the PRRS virus by indirect immunofluorescence. Briefly, 96-well plates of confluent MA104 cells were fixed with 80% acetone for 10 minutes at 2 days after infection with each virus. Monolayers were then incubated with SD0W17, V017, or EP147 monoclonal antibodies. Following washing, monoclonal antibody reactivity with each virus was detected by incubation with fluorescein isothiocyanate conjugated anti-mouse IgG followed by washing and examination for fluorescence by microscopy. Positive fluorescence was noted with all three monoclonal antibodies for the NEB-1 parental strain (Table 2) . However, the vaccine strain, NEB-1-P94, had lost reactivity with the SD0W17 monoclonal antibody but tested positive with the other two monoclonal antibodies. These data indicate that the NEB-1- P94 strain had lost expression of epitope recognized by the SD0W17 antibody. The loss of reactivity with this monoclonal antibody most likely represents genetic mutation in the RNA sequence of NEB-1-P94 which resulted in an altered amino acid sequence in the nucleocapsid protein region recognized by SD0W17.
Table 2. Reactivity of Parental and Vaccine Strain PRRS with Specific Monoclonal Antibodies.
Figure imgf000012_0001
EXAMPLE 4
Prevention of Reproductive Disease by Vaccination of Sows with NEB-1-P94
Vaccine was prepared by inoculation of confluent roller bottles of MA104 cells with NEB-1-P94 (4 passages from the master seed) at a multiplicity of infection of approximately 1:10 in EMEM containing 10% fetal bovine serum, 2 mM L-glutamine, and 30 μg/ml gentamicin. Cultures were incubated for three days at 37°C and then supernatant fluids were harvested by decanting. Virus fluids were diluted 50% (v/v) with stabilizer (75 g/L tryptone, 30 g/L dextran, 2 g/L gelatin, 100 g/L lactose, 2 g/L sodium gluta ate, 1.05 g/L KH2PO4, 2.5 g/L K2HP04, lOg/L albumin fraction V) , frozen, and lyophilized. Vaccine was rehydrated with sterile deionized water and 2 ml (105-1 TCIDsrj/ml) administered intramuscularly to gilts four to six weeks prior to breeding.
At 85 days of gestation, vaccinated and unvaccinated control gilts were challenged by intranasal administration of NEB-1 virus (approximately 106-3 TCID50) • Animals were monitored through seven weeks after farrowing for signs of fetal or neonatal death attributed to PRRS virus. PRRS viremia developed in 11/12 (92%) of control sows and 100% of their live-born piglets. PRRS infection during pregnancy resulted in 16% death loss at parturition (large mummies and stillborn pigs) in the control group (Table 3) compared to only 6% death loss in vaccinated sows. In addition, vaccination resulted in a 50% reduction in the incidence of weak and shaky piglets and 94% reduction in piglets with low birth weights (weighing less than 2 pounds at birth) when compared to controls. Vaccination prevented congenital PRRS as evidenced by the absence of PRRS virus in blood or tissues of any piglets from immunized sows and a 55% prevention of death loss through 7 weeks of age (Table 3) when compared to controls. The statistically significant prevention of death loss and virus infection in vaccinated sows and their offspring clearly demonstrated the efficacy of this vaccine in preventing the reproductive form of PRRS virus-induced disease. Table 3. Summary of Reproductive Disease Noted After PRRS Virus Challenge of Vaccinated versus Control Sows
Group Number of Sows % Large % Born % Weak % Piglets 7 Week (Ave # Pigs/Litter) Mummies and Live but and Weighing <2 Mortality
Stillborn Died Shaky lbs.
Vaccinated 21 (10.8) 6% 2% 3% 1% 17%
Controls 12 (10.1) 16% 3% 6% 17% 38%
EXAMPLE 5
Prevention of Respiratory Disease by Vaccination of Sows with
NEB-1-P94
Vaccine was prepared by inoculation of confluent roller bottles of MA104 cells with NEB-1-P94 (at 4 passages from the master seed) at a multiplicity of infection of approximately 1:10 in EMEM containing 10% fetal bovine serum, 2 mM L-glutamine, and 30 μg/ml gentamicin. Cultures were incubated for five days at 37°C and then supernatant fluids were harvested by decanting. Virus fluids were diluted 50% (v/v) with stabilizer (75 g/L tryptone, 30 g/L dextran, 2 g/L gelatin, 100 g/L lactose, 2 g/L sodium glutamate, 1.05 g/L KH2PO4, 2.5 g/L K2HP04, 10 g/L albumin fraction V) , frozen, and lyophilized. Vaccine was rehydrated with sterile deionized water and 1 ml (104-9 TCID50/ml) administered intramuscularly to PRRS seronegative piglets at three weeks of age.
Four weeks following vaccination, piglets were challenged with virulent NEB-1 PRRS virus by intranasal route as described for gilts (Example 4) . Piglets were monitored for respiratory disease signs for 14 days after challenge. All unvaccinated control piglets developed clinical signs of respiratory disease compared with 3/40 (8%) of vaccinated animals. Vaccination resulted in a statistically significant reduction in fever, respiratory signs, and clinical illness in vaccinated animals compared to controls (Table 4) . This study clearly demonstrated the efficacy of the vaccine in the prevention of respiratory disease caused by PRRS virus in young pigs. Table 4. Summary of Clinical Disease in Vaccinated and Control Animals Following PRRS Virus Challenge
Percentage of Animals w rith Clinical Signs on Indicated Days
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Respiratory Signs
Controls 0 0 0 57 53 37 60 40 37 40 47 40 23 30 33
Vaccinates 0 0 0 8 8 0 2 8 0 2 5 5 5 2 0
Fever >104.5°F
I
Controls 3 17 43 73 83 73 66 50 37 57 47 37 20 17 NA
Vaccinates 0 14 20 20 14 10 10 20 2 14 10 10 4 4 NA
Clniical Illness
Controls 0 0 0 23 60 50 60 47 33 50 50 40 33 27 33
Vaccinates 0 0 0 2 0 0 0 2 0 2 2 2 0 0 0
rtt * Data not avatfaUβ Controls n«30 Vacdnatββ n-40

Claims

CLAIMS :
1. A vaccine suitable for use in the protection of swine against porcine reproductive and respiratory syndrome comprising a PRRS virus essentially corresponding to the isolate NEB-1-P94, deposited at the American Type Culture Collection under accession number VR-2525.
2. The vaccine of Claim 1 which is in a live, killed or modified live (attenuated) form.
3. The vaccine of Claim 2 wherein the viral agent is modified live (attenuated) and is in a liquid, frozen or dessicated form.
4. The vaccine of Claim 1 containing an amount of 104-0 to 109-0 TCID50 of the PRRS virus per ml.
5. The vaccine of Claim 1 where the attenuated virus can be distinguished from wild type forms of the virus based on lack of reactivity with monoclonal antibody SDOW17 and lack of efficient growth on swine alveolar macrophage cells .
6. A method of protecting a pig from clinical disease caused by the porcine reproductive and respiratory syndrome virus comprising administering an effective amount of vaccine of Claim 1 to a pig in need of precaution against disease caused by said virus.
7. A method of claim 6 wherein said vaccine is administered orally, intranasally, intramuscularly, intradermally, intravenously, or subcutaneously.
8. A method of of diagnosing infection with only the vaccine virus of claim 1 versus infection with wild type virus based on isolation of virus from serum or tissue of an infected pig and phenotypic characterization as specified in claim 5.
9. A method of claim 8 wherein diagnosis of infection with vaccine virus or wild type virus comprises by measurement of antibodies in the infected swine that are reactive with the PRRS virus protein epitope recognized by monoclonal antibody SD0W17.
PCT/US1997/002562 1996-03-01 1997-02-26 Porcine reproductive and respiratory syndrome vaccine WO1997031651A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
KR1019980706853A KR100297537B1 (en) 1996-03-01 1997-02-26 Pig reproductive and respiratory syndrome vaccine
EE9800267A EE04741B1 (en) 1996-03-01 1997-02-26 Vaccine for porcine reproductive and respiratory syndrome
AU22774/97A AU2277497A (en) 1996-03-01 1997-02-26 Porcine reproductive and respiratory syndrome vaccine
BRPI9708443-3A BR9708443B1 (en) 1996-03-01 1997-02-26 vaccine against reproductive and respiratory syndrome in pigs.
SK1194-98A SK119498A3 (en) 1996-03-01 1997-02-26 Porcine reproductive and respiratory syndrome vaccine
JP09530994A JP3135069B2 (en) 1996-03-01 1997-02-26 Swine reproductive and respiratory syndrome vaccine
EP97906016A EP0894007A1 (en) 1996-03-01 1997-02-26 Porcine reproductive and respiratory syndrome vaccine
CA002248182A CA2248182C (en) 1996-03-01 1997-02-26 Porcine reproductive and respiratory syndrome vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60980696A 1996-03-01 1996-03-01
US08/609,806 1996-03-01

Publications (1)

Publication Number Publication Date
WO1997031651A1 true WO1997031651A1 (en) 1997-09-04

Family

ID=24442410

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/002562 WO1997031651A1 (en) 1996-03-01 1997-02-26 Porcine reproductive and respiratory syndrome vaccine

Country Status (19)

Country Link
EP (1) EP0894007A1 (en)
JP (1) JP3135069B2 (en)
KR (1) KR100297537B1 (en)
CN (1) CN1165342C (en)
AR (1) AR006023A1 (en)
AU (1) AU2277497A (en)
BG (1) BG64693B1 (en)
BR (1) BR9708443B1 (en)
CA (1) CA2248182C (en)
CO (1) CO4600644A1 (en)
CZ (1) CZ273798A3 (en)
EE (1) EE04741B1 (en)
HU (1) HUP9901958A3 (en)
MY (1) MY115070A (en)
PL (1) PL328627A1 (en)
RU (1) RU2187333C2 (en)
SK (1) SK119498A3 (en)
WO (1) WO1997031651A1 (en)
ZA (1) ZA971663B (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500662B1 (en) 1998-12-22 2002-12-31 Pfizer Inc. Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US8383131B2 (en) 2004-09-21 2013-02-26 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome isolates and methods of use
US8399187B2 (en) 2004-06-18 2013-03-19 Regents Of The University Of Minnesota Identifying virally infected and vaccinated organisms
US8546124B2 (en) 1996-10-30 2013-10-01 Boehringer Ingelheim Vetmedica Gmbh Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US8741309B2 (en) 1999-04-22 2014-06-03 The United States Of America As Represented By The Secretary Of Agriculture Porcine reproductive and respiratory syndrome vaccine based on isolate JA-142
US8765142B2 (en) 2011-02-17 2014-07-01 Boehringer Ingelheim Vetmedica Gmbh European PRRSV strain
US8790656B2 (en) 1996-10-30 2014-07-29 Boehringer Ingelheim Vetmedica Gmbh PRRSV vaccines
US9080143B2 (en) 2005-06-24 2015-07-14 University Of Minnesota PRRS viruses, infectious clones, mutants thereof, and method of use
US9187731B2 (en) 2011-07-29 2015-11-17 Boehringer Ingelheim Vetmedica Gmbh PRRS virus inducing type I interferon in susceptible cells
US9315781B2 (en) 2011-07-29 2016-04-19 Boehringer Ingelheim Vetmedica Gmbh Infectious CDNA clone of european PRRS virus and uses thereof
US9561270B2 (en) 2009-09-02 2017-02-07 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing virucidal activity in PCV-2 compositions and PCV-2 compositions with an improved immunogenicity
US9579373B2 (en) 2013-03-15 2017-02-28 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
US9944902B2 (en) 2011-02-17 2018-04-17 Boehringer Ingelheim Vetmedica Gmbh Commercial scale process for production of PRRSV
EP4012025A1 (en) * 2020-12-10 2022-06-15 Univerzita Palackého v Olomouci Transport medium for samples containing nucleic acids and/or proteins
CZ309704B6 (en) * 2020-12-10 2023-08-09 Univerzita Palackého v Olomouci Transport medium for virus transport and storage

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2354333C1 (en) * 2007-07-24 2009-05-10 ФГОУ ВПО Омский государственный аграрный университет Method for early diagnostics of postnatal diseases in sows
CN101612395B (en) * 2008-06-24 2012-02-08 扬州优邦生物制药有限公司 Method for producing blue-ear disease vaccine by culturing sensitive cell
KR101300528B1 (en) * 2011-10-05 2013-09-02 캔 테크놀로지스 인코포레이티드 Composition for prevention and treatment of Actinobacillus pleuropneumoniae infection

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007898A1 (en) * 1991-10-14 1993-04-29 Akzo Nobel N.V. Porcine reproductive respiratory syndrome vaccine and diagnostic
WO1993014196A1 (en) * 1992-01-14 1993-07-22 Rhone Merieux S.A. Preparation of mystery disease virus antigens and vaccines and antigens and vaccines produced for the prevention of this disease
EP0595436A2 (en) * 1992-10-30 1994-05-04 Solvay Animal Health, Inc. Porcine respiratory and reproductive disease virus, vaccines and viral DNA
WO1994018311A1 (en) * 1993-02-08 1994-08-18 Bayer Corporation Process for growing porcine reproductive and respiratory syndrome virus and its use in vaccines
GB2282811A (en) * 1993-09-17 1995-04-19 Iberica Cyanamid Viral vaccine for the prevention of porcine reproductive and respiratory syndrome
EP0676467A2 (en) * 1994-04-11 1995-10-11 Akzo Nobel N.V. European vaccine strains of the porcine reproductive respiratory syndrome virus (PRRSV)
WO1996036356A1 (en) * 1995-05-15 1996-11-21 Boehringer Ingelheim Corporation Viral agent associated with mystery swine disease
WO1997000696A1 (en) * 1995-06-21 1997-01-09 Regents Of The University Of Minnesota Low pathogenicity prrs live virus vaccines and methods of preparation thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007898A1 (en) * 1991-10-14 1993-04-29 Akzo Nobel N.V. Porcine reproductive respiratory syndrome vaccine and diagnostic
WO1993014196A1 (en) * 1992-01-14 1993-07-22 Rhone Merieux S.A. Preparation of mystery disease virus antigens and vaccines and antigens and vaccines produced for the prevention of this disease
EP0595436A2 (en) * 1992-10-30 1994-05-04 Solvay Animal Health, Inc. Porcine respiratory and reproductive disease virus, vaccines and viral DNA
WO1994018311A1 (en) * 1993-02-08 1994-08-18 Bayer Corporation Process for growing porcine reproductive and respiratory syndrome virus and its use in vaccines
GB2282811A (en) * 1993-09-17 1995-04-19 Iberica Cyanamid Viral vaccine for the prevention of porcine reproductive and respiratory syndrome
EP0676467A2 (en) * 1994-04-11 1995-10-11 Akzo Nobel N.V. European vaccine strains of the porcine reproductive respiratory syndrome virus (PRRSV)
WO1996036356A1 (en) * 1995-05-15 1996-11-21 Boehringer Ingelheim Corporation Viral agent associated with mystery swine disease
WO1997000696A1 (en) * 1995-06-21 1997-01-09 Regents Of The University Of Minnesota Low pathogenicity prrs live virus vaccines and methods of preparation thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BEILAGE, E.G.: "DIE BEDEUTUNG DES PRRS-VIRUS FÜR ERKRANKUNGEN DES RESPIRATIONSTRAKTES BEIM SCHWEIN - EINE LITERATURÜBERSICHT", DEUTSCHE TIERÄRZTLICHE WOCHENSCHRIFT, vol. 102, no. 12, 1995, pages 457 - 469, XP000654400 *
MENG, X.-J. ET AL.: "SEQUENCE COMPARISON OF OPEN READING FRAMES 2 TO 5 OF LOW AND HIGH VIRULENCE UNITED STATES ISOLATES OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS", JOURNAL OF GENERAL VIROLOGY, vol. 76, 1995, pages 3181 - 3188, XP000654509 *
NELSON, E.A. ET AL.: "DIFFERENTIATION OF U.S. AND EUROPEAN ISOLATES OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS BY MONOCLONAL ANTIBODIES", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 31, no. 12, 1993, pages 3184 - 3189, XP000654506 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8790656B2 (en) 1996-10-30 2014-07-29 Boehringer Ingelheim Vetmedica Gmbh PRRSV vaccines
US8546124B2 (en) 1996-10-30 2013-10-01 Boehringer Ingelheim Vetmedica Gmbh Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US6500662B1 (en) 1998-12-22 2002-12-31 Pfizer Inc. Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US8741309B2 (en) 1999-04-22 2014-06-03 The United States Of America As Represented By The Secretary Of Agriculture Porcine reproductive and respiratory syndrome vaccine based on isolate JA-142
US8747859B2 (en) 1999-04-22 2014-06-10 The United States Of America, As Represented By The Secretary Of Agriculture Porcine reproductive and respiratory syndrome vaccine based on isolate JA-142
US8399187B2 (en) 2004-06-18 2013-03-19 Regents Of The University Of Minnesota Identifying virally infected and vaccinated organisms
US8383131B2 (en) 2004-09-21 2013-02-26 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome isolates and methods of use
US9080143B2 (en) 2005-06-24 2015-07-14 University Of Minnesota PRRS viruses, infectious clones, mutants thereof, and method of use
US9561270B2 (en) 2009-09-02 2017-02-07 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing virucidal activity in PCV-2 compositions and PCV-2 compositions with an improved immunogenicity
US8765142B2 (en) 2011-02-17 2014-07-01 Boehringer Ingelheim Vetmedica Gmbh European PRRSV strain
US9944902B2 (en) 2011-02-17 2018-04-17 Boehringer Ingelheim Vetmedica Gmbh Commercial scale process for production of PRRSV
US10668144B2 (en) 2011-02-17 2020-06-02 Boehringer Ingelheim Vetmedica Gmbh European PRRSV strain
US9187731B2 (en) 2011-07-29 2015-11-17 Boehringer Ingelheim Vetmedica Gmbh PRRS virus inducing type I interferon in susceptible cells
US9315781B2 (en) 2011-07-29 2016-04-19 Boehringer Ingelheim Vetmedica Gmbh Infectious CDNA clone of european PRRS virus and uses thereof
US9579373B2 (en) 2013-03-15 2017-02-28 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
EP4012025A1 (en) * 2020-12-10 2022-06-15 Univerzita Palackého v Olomouci Transport medium for samples containing nucleic acids and/or proteins
CZ309704B6 (en) * 2020-12-10 2023-08-09 Univerzita Palackého v Olomouci Transport medium for virus transport and storage

Also Published As

Publication number Publication date
KR19990087432A (en) 1999-12-27
MX9807083A (en) 1998-12-31
BR9708443B1 (en) 2012-06-12
BG102809A (en) 1999-05-31
CN1216922A (en) 1999-05-19
HUP9901958A3 (en) 2000-04-28
BR9708443A (en) 1999-08-03
SK119498A3 (en) 1999-07-12
CA2248182C (en) 2004-04-20
MY115070A (en) 2003-03-31
EP0894007A1 (en) 1999-02-03
CO4600644A1 (en) 1998-05-08
HUP9901958A2 (en) 1999-10-28
CA2248182A1 (en) 1997-09-04
AR006023A1 (en) 1999-07-21
EE9800267A (en) 1999-02-15
JPH11506122A (en) 1999-06-02
CZ273798A3 (en) 1999-02-17
RU2187333C2 (en) 2002-08-20
EE04741B1 (en) 2006-12-15
ZA971663B (en) 1997-08-26
KR100297537B1 (en) 2001-10-26
AU2277497A (en) 1997-09-16
PL328627A1 (en) 1999-02-15
CN1165342C (en) 2004-09-08
JP3135069B2 (en) 2001-02-13
BG64693B1 (en) 2005-12-30

Similar Documents

Publication Publication Date Title
US5866401A (en) Porcine reproductive and respiratory syndrome vaccine
CA2248182C (en) Porcine reproductive and respiratory syndrome vaccine
EP0830142B1 (en) Prrs (porcine reproductive and respiratory syndrome) virus vaccine
US5690940A (en) Low pathogencity PRRS live virus vaccines and methods of preparation thereof
US5698203A (en) European vaccine strains of the Porcine Reproductive Respiratory Syndrome virus (PRRSV)
EP0601062B1 (en) Sirs vaccine and diagnosis method
CA2076744C (en) Viral agent associated with mystery swine disease
US6498008B2 (en) Method for detecting swine infertility and respiratory virus
US7264957B2 (en) Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV), proteins encoded by the polynucleic acids, vaccines based on the proteins and/or polynucleic acids, a method of protecting a pig from a PRRSV and a method of detecting a PRRSV
US7517976B2 (en) Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV)
US6001370A (en) Attenuated strain of the virus causing the porcine reproductive respiratory syndrome (PRRS), and vaccines
US20150276737A1 (en) Immunogenic compositions including SIRS virus
HK1005014B (en) Sirs vaccine and diagnosis method
US8178103B2 (en) Porcine reproductive and respiratory syndrome virus strains and compositions
Sestak et al. Porcine coronaviruses
Pensaert Porcine epidemic diarrhea
MXPA98007083A (en) Vaccine against the reproductive and respiratory syndrome porc
MXPA97010149A (en) Live pathogenicity live virus vaccines and methods of preparation of mis

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97194109.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CZ EE GE HU IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997906016

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV1998-2737

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2248182

Country of ref document: CA

Ref document number: 2248182

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 119498

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/007083

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 1997 530994

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019980706853

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1997906016

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1998-2737

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019980706853

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1019980706853

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997906016

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1998-2737

Country of ref document: CZ